Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.

Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D.

Alzheimers Res Ther. 2019 Aug 7;11(1):68. doi: 10.1186/s13195-019-0520-1.

2.

Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.

Herring WJ, Connor KM, Snyder E, Snavely DB, Morin CM, Lines C, Michelson D.

Sleep Med. 2019 Apr;56:219-223. doi: 10.1016/j.sleep.2018.09.010. Epub 2018 Oct 2.

PMID:
30522875
3.

Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis.

Molina-Molina M, Aburto M, Acosta O, Ancochea J, Rodríguez-Portal JA, Sauleda J, Lines C, Xaubet A.

Expert Rev Respir Med. 2018 Jul;12(7):537-539. doi: 10.1080/17476348.2018.1472580. Epub 2018 May 7. No abstract available.

PMID:
29718749
4.

Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.

Svetnik V, Snyder ES, Tao P, Scammell TE, Roth T, Lines C, Herring WJ.

Sleep. 2018 Jan 1;41(1). doi: 10.1093/sleep/zsx178.

PMID:
29112763
5.

A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.

Herring WJ, Assaid C, Budd K, Vargo R, Mazenko RS, Lines C, Ellenbogen A, Verhagen Metman L.

Clin Neuropharmacol. 2017 Nov/Dec;40(6):255-260. doi: 10.1097/WNF.0000000000000241.

PMID:
29059133
6.

National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014.

Nguyen DB, Shugart A, Lines C, Shah AB, Edwards J, Pollock D, Sievert D, Patel PR.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1139-1146. doi: 10.2215/CJN.11411116. Epub 2017 Jun 29.

7.

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.

Connor KM, Ceesay P, Hutzelmann J, Snavely D, Krystal AD, Trivedi MH, Thase M, Lines C, Herring WJ, Michelson D.

Int J Neuropsychopharmacol. 2017 Aug 1;20(8):613-618. doi: 10.1093/ijnp/pyx033.

8.

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group.

Neurology. 2017 Jun 6;88(23):2198-2206. doi: 10.1212/WNL.0000000000004003. Epub 2017 May 10.

PMID:
28490648
9.

Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.

Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D.

Am J Geriatr Psychiatry. 2017 Jul;25(7):791-802. doi: 10.1016/j.jagp.2017.03.004. Epub 2017 Mar 8.

PMID:
28427826
10.

Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.

Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D.

Psychopharmacology (Berl). 2017 Jun;234(11):1703-1711. doi: 10.1007/s00213-017-4573-1. Epub 2017 Mar 7.

PMID:
28265715
11.

EEG spectral analysis of NREM sleep in a large sample of patients with insomnia and good sleepers: effects of age, sex and part of the night.

Svetnik V, Snyder ES, Ma J, Tao P, Lines C, Herring WJ.

J Sleep Res. 2017 Feb;26(1):92-104. doi: 10.1111/jsr.12448. Epub 2016 Sep 16.

12.

Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.

Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D.

J Clin Sleep Med. 2016 Sep 15;12(9):1215-25. doi: 10.5664/jcsm.6116.

13.

Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.

Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, Herring WJ.

Sleep Med. 2016 Mar;19:93-100. doi: 10.1016/j.sleep.2015.10.007. Epub 2015 Nov 10.

PMID:
27198953
14.

Sustained Infection Reduction in Outpatient Hemodialysis Centers Participating in a Collaborative Bloodstream Infection Prevention Effort.

Yi SH, Kallen AJ, Hess S, Bren VR, Lincoln ME, Downham G, Kelley K, Booth SL, Weirich H, Shugart A, Lines C, Melville A, Jernigan JA, Kleinbaum DG, Patel PR.

Infect Control Hosp Epidemiol. 2016 Jul;37(7):863-6. doi: 10.1017/ice.2016.22. Epub 2016 Feb 12.

PMID:
26868605
15.

Completeness of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection Reporting From Outpatient Hemodialysis Facilities to the National Healthcare Safety Network, 2013.

Nguyen DB, See I, Gualandi N, Shugart A, Lines C, Bamberg W, Dumyati G, Harrison LH, Lesher L, Nadle J, Petit S, Ray SM, Schaffner W, Townes J, Njord L, Sievert D, Thompson ND, Patel PR.

Infect Control Hosp Epidemiol. 2016 Feb;37(2):205-7. doi: 10.1017/ice.2015.265. Epub 2015 Nov 11.

16.

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.

Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D.

JAMA Neurol. 2015 Dec;72(12):1491-500. doi: 10.1001/jamaneurol.2015.2268.

PMID:
26523919
17.

Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.

Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD.

J Clin Sleep Med. 2016 Jan;12(1):9-17. doi: 10.5664/jcsm.5382.

18.

Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine.

Ho TW, Ho AP, Ge YJ, Assaid C, Gottwald R, MacGregor EA, Mannix LK, van Oosterhout WP, Koppenhaver J, Lines C, Ferrari MD, Michelson D.

Cephalalgia. 2016 Feb;36(2):148-61. doi: 10.1177/0333102415584308. Epub 2015 Apr 29.

PMID:
25926620
19.

Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.

Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, Louridas B, Marsilio S, Lines C, Troyer MD, Wagner J.

J Clin Pharmacol. 2015 Oct;55(10):1093-100. doi: 10.1002/jcph.523. Epub 2015 Jun 3.

PMID:
25903940
20.

Exploring the role of communications in quality improvement: A case study of the 1000 Lives Campaign in NHS Wales.

Cooper A, Gray J, Willson A, Lines C, McCannon J, McHardy K.

J Commun Healthc. 2015 Mar;8(1):76-84.

21.

Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.

Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD.

Respir Med. 2015 Mar;109(3):416-26. doi: 10.1016/j.rmed.2014.12.010. Epub 2015 Jan 5.

22.

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D.

Biol Psychiatry. 2016 Jan 15;79(2):136-48. doi: 10.1016/j.biopsych.2014.10.003. Epub 2014 Oct 23.

PMID:
25526970
23.

Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.

Ball WA, Snavely DB, Hargreaves RJ, Szegedi A, Lines C, Reines SA.

Hum Psychopharmacol. 2014 Nov;29(6):568-77. doi: 10.1002/hup.2444. Epub 2014 Oct 20.

PMID:
25330122
24.

Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.

Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ.

Sleep. 2014 Oct 1;37(10):1609-19. doi: 10.5665/sleep.4068.

25.

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.

Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D.

Neurology. 2014 Sep 9;83(11):958-66. doi: 10.1212/WNL.0000000000000771. Epub 2014 Aug 8.

PMID:
25107879
26.

Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis.

Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D.

Cephalalgia. 2015 Apr;35(5):379-88. doi: 10.1177/0333102414544979. Epub 2014 Aug 8.

PMID:
25106663
27.

Combined reflectance spectroscopy and stochastic modeling approach for noninvasive hemoglobin determination via palpebral conjunctiva.

Kim O, McMurdy J, Jay G, Lines C, Crawford G, Alber M.

Physiol Rep. 2014 Jan 8;2(1):e00192. doi: 10.1002/phy2.192. eCollection 2014 Jan 1.

28.

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ.

Lancet Neurol. 2014 May;13(5):461-71. doi: 10.1016/S1474-4422(14)70053-5. Epub 2014 Mar 27.

PMID:
24680372
29.

Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients.

Sun H, MacLeod C, Mostoller K, Mahon C, Han L, Renger JJ, Ma J, Brown KR, Schulz V, Kay GG, Herring WJ, Lines C, Rosen LB, Murphy MG, Wagner JA.

J Clin Pharmacol. 2013 Dec;53(12):1294-302. doi: 10.1002/jcph.182. Epub 2013 Oct 4.

PMID:
24122944
30.

Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.

Herring WJ, Liu K, Hutzelmann J, Snavely D, Snyder E, Ceesay P, Lines C, Michelson D, Roth T.

Sleep Med. 2013 Oct;14(10):955-63. doi: 10.1016/j.sleep.2013.04.010. Epub 2013 Aug 3.

PMID:
23920422
31.

Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.

Egan MF, Zhao X, Smith A, Troyer MD, Uebele VN, Pidkorytov V, Cox K, Murphy M, Snavely D, Lines C, Michelson D.

Hum Psychopharmacol. 2013 Mar;28(2):124-33. doi: 10.1002/hup.2289.

PMID:
23532746
32.

Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.

F Egan M, Zhao X, Gottwald R, Harper-Mozley L, Zhang Y, Snavely D, Lines C, Michelson D.

Schizophr Res. 2013 May;146(1-3):224-30. doi: 10.1016/j.schres.2013.02.030. Epub 2013 Mar 22.

PMID:
23523692
33.

Composite endpoints for detecting meaningful changes in trials of headache treatments.

Lines C.

Cephalalgia. 2013 May;33(7):499. doi: 10.1177/0333102413480953. Epub 2013 Mar 14. No abstract available.

PMID:
23493763
34.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM.

Sleep. 2013 Feb 1;36(2):259-67. doi: 10.5665/sleep.2386.

35.

Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.

Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D.

Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28.

PMID:
23197752
36.

Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs.

Hewitt DJ, Pearlman E, Hämäläinen M, Lewis D, Connor KM, Michelson D, Ceesay P, Assaid C, Bachman R, Harper Mozley L, Dupre N, Strickler N, Mahoney E, Lines C, Ho TW.

Headache. 2013 Jan;53(1):104-117. doi: 10.1111/j.1526-4610.2012.02285.x. Epub 2012 Oct 18.

PMID:
23078588
37.

Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.

Herring WJ, Wilens TE, Adler LA, Baranak C, Liu K, Snavely DB, Lines CR, Michelson D.

J Clin Psychiatry. 2012 Jul;73(7):e891-8. doi: 10.4088/JCP.11m07178.

PMID:
22901359
38.

Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.

Ho TW, Pearlman E, Lewis D, Hämäläinen M, Connor K, Michelson D, Zhang Y, Assaid C, Mozley LH, Strickler N, Bachman R, Mahoney E, Lines C, Hewitt DJ; Rizatriptan Protocol 082 Pediatric Migraine Study Group.

Cephalalgia. 2012 Jul;32(10):750-65. Epub 2012 Jun 18.

PMID:
22711898
39.

Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.

Michelson D, Hargreaves R, Alexander R, Ceesay P, Hietala J, Lines C, Reines S.

Int J Neuropsychopharmacol. 2013 Feb;16(1):1-11. doi: 10.1017/S1461145712000065. Epub 2012 Mar 20.

PMID:
22433185
40.

Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.

Chabi A, Varma R, Tsai JC, Lupinacci R, Pigeon J, Baranak C, Noble L, Lines C, Ho TW.

Am J Ophthalmol. 2012 Jun;153(6):1187-96. doi: 10.1016/j.ajo.2011.11.008. Epub 2012 Feb 4.

PMID:
22310086
41.

Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.

Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, Michelson D.

Curr Alzheimer Res. 2012 May;9(4):481-90.

PMID:
22272611
42.

Reflectance spectrometry of normal and bruised human skins: experiments and modeling.

Kim O, McMurdy J, Lines C, Duffy S, Crawford G, Alber M.

Physiol Meas. 2012 Feb;33(2):159-75. doi: 10.1088/0967-3334/33/2/159. Epub 2012 Jan 19.

PMID:
22258326
43.

Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.

Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora SK, Brandes JL, Fei K, Beebe L, Lines C, Krucoff MW.

Headache. 2012 Feb;52(2):224-35. doi: 10.1111/j.1526-4610.2011.02052.x. Epub 2012 Jan 6.

PMID:
22221076
44.

Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans.

Cho W, Maruff P, Connell J, Gargano C, Calder N, Doran S, Fox-Bosetti S, Hassan A, Renger J, Herman G, Lines C, Verma A.

Psychopharmacology (Berl). 2011 Dec;218(3):513-24. doi: 10.1007/s00213-011-2344-y. Epub 2011 Jun 7.

PMID:
21644059
45.

Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine.

Hewitt DJ, Martin V, Lipton RB, Brandes J, Ceesay P, Gottwald R, Schaefer E, Lines C, Ho TW.

Headache. 2011 Apr;51(4):533-43. doi: 10.1111/j.1526-4610.2011.01860.x.

PMID:
21457238
46.

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine.

Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW.

Cephalalgia. 2011 Apr;31(6):712-22. doi: 10.1177/0333102411398399. Epub 2011 Mar 7.

PMID:
21383045
47.

The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects.

Han TH, Blanchard RL, Palcza J, Martucci A, Miller-Stein CM, Gutierrez M, Panebianco D, Rippley RK, Lines C, Murphy MG.

Arch Drug Inf. 2010 Dec;3(4):55-62.

48.

Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.

Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H, Massaad R, Williams-Diaz A, Lines C, Ho TW.

Headache. 2011 Jan;51(1):73-84. doi: 10.1111/j.1526-4610.2010.01799.x. Epub 2010 Nov 10.

PMID:
21070230
49.

Antimigraine efficacy of telcagepant based on patient's historical triptan response.

Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD.

Headache. 2011 Jan;51(1):64-72. doi: 10.1111/j.1526-4610.2010.01790.x. Epub 2010 Nov 4.

PMID:
21054362
50.

Randomized, controlled trial of telcagepant over four migraine attacks.

Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW.

Cephalalgia. 2010 Dec;30(12):1443-57. doi: 10.1177/0333102410370878. Epub 2010 Jun 8.

PMID:
20974601

Supplemental Content

Support Center